Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization

被引：0
|
作者：
Neville, Grace [1 ]
O'Connell, Fionnuala [1 ]
Bennett, Michael [1 ]
Feeley, Linda
O'Reilly, Seamus [1 ]
Browne, Tara Jane [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
268
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [31] HEr2 testing in neoadjuvant breast cancer trials - improved concordance of HER2 status in different pathology laboratories
    Pfitzner, B.
    Lederer, B.
    Lindner, J.
    Solbach, C.
    Engels, K.
    Rezai, M.
    Dohnal, K.
    Tesch, H.
    Hansmann, M. -L.
    Salat, C.
    Beer, M.
    Schneeweiss, A.
    Sinn, P.
    von Minckwitz, G.
    Denkert, C.
    Loibl, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 56 - 56
  • [32] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    LABORATORY INVESTIGATION, 2018, 98 : 54 - 54
  • [33] HER2 copy number on FISH as a predictor of disease severity in HER2-breast cancer
    Abedin, S.
    Kruse, M.
    Brufsky, A.
    Bhargava, R.
    CANCER RESEARCH, 2013, 73
  • [34] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
    Apple, Sophia
    Murata-Collins, Joyce
    LABORATORY INVESTIGATION, 2018, 98 : 45 - 45
  • [35] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
    Apple, Sophia
    Murata-Collins, Joyce
    MODERN PATHOLOGY, 2018, 31 : 45 - 45
  • [36] Performance of Automated Brightfield Dual Color In Situ Hybridization (ISH) for Detection of HER2 Gene Amplification in Breast Carcinoma
    Nitta, H.
    Hauss-Wegrzyniak, B.
    Lehrkamp, M.
    Murillo, A.
    Farrell, M.
    Kurosumi, M.
    Walk, E.
    Dietel, M.
    Penault-Llorca, F.
    Loftus, M.
    Wang, L.
    Pettay, J.
    Tubbs, R.
    Grogan, T.
    MODERN PATHOLOGY, 2009, 22 : 60A - 60A
  • [37] Performance of Automated Brightfield Dual Color In Situ Hybridization (ISH) for Detection of HER2 Gene Amplification in Breast Carcinoma
    Nitta, H.
    Hauss-Wegrzyniak, B.
    Lehrkamp, M.
    Murillo, A.
    Farrell, M.
    Kurosumi, M.
    Walk, E.
    Dietel, M.
    Penault-Llorca, F.
    Loftus, M.
    Wang, L.
    Pettay, J.
    Tubbs, R.
    Grogan, T.
    LABORATORY INVESTIGATION, 2009, 89 : 60A - 60A
  • [38] HER2 in-Situ hybridization positive breast cancers with HER2/CEP17 ratio ≥2.0 and average HER2 copy number <4.0 are frequently discordant with HER2 immunohistochemistry results: Implications for potential modification of testing algorithm
    Livasy, Chad
    Johnson, Nicole
    Domfeh, Akosua
    CANCER RESEARCH, 2018, 78 (04)
  • [39] Next-generation sequencing based detection of HER2 copy number predicts pathological response to neoadjuvant therapy in HER2 positive breast cancer
    Dai, Hao
    Jiao, Dechuang
    Guo, Xuhui
    Qiao, Jianghua
    Li, Anfang
    Lu, Zhenduo
    Chen, Xiuchun
    Wang, Chengzheng
    Yan, Min
    Liu, Zhenzhen
    CANCER RESEARCH, 2023, 84 (06)
  • [40] Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.
    Ran, Ran
    Huang, Wenfa
    Lin, Shao
    Niu, Yunyun
    Rugo, Hope S.
    Kong, Weiyao
    Bo, Shiping
    Lu, Sijia
    Li, Huiping
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345